Haleon PLC Sponsored ADR (H6D) AI Stock Analysis

Haleon PLC Sponsored ADR

(Frankfurt:H6D)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Margin expansion and productivity savingsImproving gross and operating margins, supported by identified operating-model savings, indicate that Haleon is strengthening profitability through repeatable productivity actions. This can support earnings growth and provide capacity to reinvest in brands, innovation, and distribution over the next several quarters.

Negative Factors

Material absolute debt burdenAlthough leverage improved, the sizeable absolute debt balance can constrain financial flexibility and compete with investment, shareholder returns, or deleveraging for available cash. If revenue growth stays modest, servicing and refinancing obligations may limit management’s ability to respond aggressively.

Haleon PLC Sponsored ADR (H6D) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 38.08B
Dividend Yield: 1.39%
Average Volume (3M): 1,145
Price to Earnings (P/E): 17.6
Beta (1Y): 0.24
Revenue Growth: -2.12%
EPS Growth: 4.78%
Country: Germany
Employees: 24,535
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Haleon PLC Sponsored ADR Business Overview & Revenue Model

Company Description

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends a...

Haleon PLC Sponsored ADR Earnings Call Summary

Earnings Call Date:Jul 29, 2026(Q2-2026)|% Change Since:-13.57%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call conveyed more positive than negative developments: solid organic growth (3.1%) with sequential improvement, robust margin expansion (gross margin +140 bps; operating margin +120 bps), strong region/product performances (Oral Care, China, India, emerging markets) and continued investment behind digital and innovation. Key headwinds—weak Respiratory (notably cough & cold), regional softness in Europe and the Middle East, and some pricing pressure in Asia—are material but portrayed as cyclical or manageable through productivity and targeted reinvestment. Management maintained guidance (3%–5% organic growth) and expressed confidence in a stronger H2.

Positive Updates

Organic sales growth and sequential improvement

Organic sales growth of 3.1% in Q2, a sequential improvement from Q1 (2.2%), with volume/mix contributing 1.4%.

Negative Updates

Respiratory health weakness

Respiratory Health was weak in Q2 and reportedly shaved ~150 basis points off organic sales growth; cough & cold (notably Contac in China) showed very little pickup and Smoker's Health continued to decline (though rate slowed).

Company Guidance

Management reiterated FY26 organic sales guidance of 3–5% (while maintaining a medium‑term ambition of 4–6%) and said H2 should be stronger than H1; Q2 organic sales were 3.1% (Q1 2.2%) with overall volume mix +1.4% and North America volume +2%, A&P in H1 grew 3.2% and sits at ~20.9% of sales with a planned step‑up in H2, and pricing is described as broadly in line with inflation and expected to be similar in H2. On margins, H1 constant‑currency operating margin improved 120 bps (gross margin +140 bps; FX +40 bps) and the company expects to deliver high‑single‑digit operating margin growth in H2, continue gross‑margin improvement while absorbing Middle East contract/hedge cost roll‑offs without exceptional pricing, and drive continued strong EPS growth after H1 EPS rose ~12%. They also reconfirmed operating‑model savings of GBP 175–200m in total, with roughly one‑third expected to fall in the current year.

Haleon PLC Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:H6D against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	67Neutral	$11.86B	40.24	7.37%	0.59%	-10.52%	-55.45%
TEVA	65Neutral	$47.43B	70.17	9.18%	―	4.40%	―
VTRS	63Neutral	$21.86B	-52.88	-2.79%	2.52%	4.92%	87.81%
AMRX	59Neutral	$7.49B	43.24	-326.75%	―	9.28%	4917.17%
PRGO	58Neutral	$2.19B	-1.26	-55.97%	7.35%	-4.18%	-2138.82%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:H6D and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:H6D	Haleon PLC Sponsored ADR	7.60	-0.25	-3.12%
RDY	Dr. Reddy's Laboratories Ltd	14.17	0.83	6.25%
VTRS	Viatris, Inc.	19.04	8.87	87.19%
PRGO	Perrigo Company	15.78	-2.98	-15.89%
TEVA	Teva Pharmaceutical Industries Limited	42.09	23.59	127.51%
AMRX	Amneal Pharma	21.51	10.32	92.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Haleon PLC Sponsored ADR AI Stock Analysis